vs
MEDIFAST INC（MED）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
MEDIFAST INC的季度营收约是RE/MAX Holdings, Inc.的1.1倍（$75.1M vs $71.1M），RE/MAX Holdings, Inc.同比增速更快（-1.8% vs -36.9%），RE/MAX Holdings, Inc.自由现金流更多（$33.5M vs $-6.6M），过去两年RE/MAX Holdings, Inc.的营收复合增速更高（-4.7% vs -34.4%）
迈德福斯特是一家总部位于美国马里兰州巴尔的摩的营养减重企业，该公司研发、分销并销售减重及健康相关产品，销售渠道涵盖官方网站、多层次营销、电话销售以及品牌加盟减重诊所。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
MED vs RMAX — 直观对比
营收规模更大
MED
是对方的1.1倍
$71.1M
营收增速更快
RMAX
高出35.1%
-36.9%
自由现金流更多
RMAX
多$40.1M
$-6.6M
两年增速更快
RMAX
近两年复合增速
-34.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.1M | $71.1M |
| 净利润 | — | $1.4M |
| 毛利率 | 69.4% | — |
| 营业利润率 | -10.4% | 13.1% |
| 净利率 | — | 2.0% |
| 营收同比 | -36.9% | -1.8% |
| 净利润同比 | — | -75.2% |
| 每股收益（稀释后） | $-1.64 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MEDRMAX
| Q4 25 | $75.1M | $71.1M | ||
| Q3 25 | $89.4M | $73.2M | ||
| Q2 25 | $105.6M | $72.8M | ||
| Q1 25 | $115.7M | $74.5M | ||
| Q4 24 | $119.0M | $72.5M | ||
| Q3 24 | $140.2M | $78.5M | ||
| Q2 24 | $168.6M | $78.5M | ||
| Q1 24 | $174.7M | $78.3M |
净利润MEDRMAX
| Q4 25 | — | $1.4M | ||
| Q3 25 | $-2.3M | $4.0M | ||
| Q2 25 | $2.5M | $4.7M | ||
| Q1 25 | $-772.0K | $-2.0M | ||
| Q4 24 | — | $5.8M | ||
| Q3 24 | $1.1M | $966.0K | ||
| Q2 24 | $-8.2M | $3.7M | ||
| Q1 24 | $8.3M | $-3.4M |
毛利率MEDRMAX
| Q4 25 | 69.4% | — | ||
| Q3 25 | 69.5% | — | ||
| Q2 25 | 72.6% | — | ||
| Q1 25 | 72.8% | — | ||
| Q4 24 | 74.1% | — | ||
| Q3 24 | 75.4% | — | ||
| Q2 24 | 73.2% | — | ||
| Q1 24 | 72.8% | — |
营业利润率MEDRMAX
| Q4 25 | -10.4% | 13.1% | ||
| Q3 25 | -4.6% | 25.0% | ||
| Q2 25 | -1.0% | 19.3% | ||
| Q1 25 | -1.1% | 7.2% | ||
| Q4 24 | 0.6% | 5.9% | ||
| Q3 24 | 1.5% | 19.4% | ||
| Q2 24 | -4.7% | 20.6% | ||
| Q1 24 | 4.5% | 5.8% |
净利率MEDRMAX
| Q4 25 | — | 2.0% | ||
| Q3 25 | -2.5% | 5.4% | ||
| Q2 25 | 2.3% | 6.4% | ||
| Q1 25 | -0.7% | -2.6% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | 0.8% | 1.2% | ||
| Q2 24 | -4.8% | 4.7% | ||
| Q1 24 | 4.8% | -4.3% |
每股收益（稀释后）MEDRMAX
| Q4 25 | $-1.64 | — | ||
| Q3 25 | $-0.21 | — | ||
| Q2 25 | $0.22 | — | ||
| Q1 25 | $-0.07 | — | ||
| Q4 24 | $0.08 | — | ||
| Q3 24 | $0.10 | — | ||
| Q2 24 | $-0.75 | — | ||
| Q1 24 | $0.76 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.3M | $118.7M |
| 总债务越低越好 | — | $432.2M |
| 股东权益账面价值 | $198.9M | $452.4M |
| 总资产 | $248.0M | $582.5M |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资MEDRMAX
| Q4 25 | $167.3M | $118.7M | ||
| Q3 25 | $173.5M | $107.5M | ||
| Q2 25 | $162.7M | $94.3M | ||
| Q1 25 | $164.6M | $89.1M | ||
| Q4 24 | $162.3M | $96.6M | ||
| Q3 24 | $170.0M | $83.8M | ||
| Q2 24 | $163.5M | $66.1M | ||
| Q1 24 | $156.4M | $82.1M |
总债务MEDRMAX
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
股东权益MEDRMAX
| Q4 25 | $198.9M | $452.4M | ||
| Q3 25 | $214.7M | $448.1M | ||
| Q2 25 | $216.0M | $442.4M | ||
| Q1 25 | $211.0M | $433.5M | ||
| Q4 24 | $210.1M | $429.5M | ||
| Q3 24 | $207.3M | $423.1M | ||
| Q2 24 | $205.3M | $418.4M | ||
| Q1 24 | $211.0M | $412.0M |
总资产MEDRMAX
| Q4 25 | $248.0M | $582.5M | ||
| Q3 25 | $268.2M | $582.2M | ||
| Q2 25 | $269.3M | $574.8M | ||
| Q1 25 | $280.0M | $571.4M | ||
| Q4 24 | $284.2M | $581.6M | ||
| Q3 24 | $291.2M | $578.6M | ||
| Q2 24 | $293.5M | $571.4M | ||
| Q1 24 | $302.8M | $566.7M |
负债/权益比MEDRMAX
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.3M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $-6.6M | $33.5M |
| 自由现金流率自由现金流/营收 | -8.8% | 47.1% |
| 资本支出强度资本支出/营收 | 1.8% | 10.4% |
| 现金转化率经营现金流/净利润 | — | 28.39× |
| 过去12个月自由现金流最近4个季度 | $1.2M | $56.8M |
8季度趋势，按日历期对齐
经营现金流MEDRMAX
| Q4 25 | $-5.3M | $40.9M | ||
| Q3 25 | $12.1M | $17.7M | ||
| Q2 25 | $-3.4M | $4.6M | ||
| Q1 25 | $3.4M | $5.7M | ||
| Q4 24 | $-4.9M | $59.7M | ||
| Q3 24 | $9.1M | $17.6M | ||
| Q2 24 | $13.1M | $15.9M | ||
| Q1 24 | $7.3M | $9.4M |
自由现金流MEDRMAX
| Q4 25 | $-6.6M | $33.5M | ||
| Q3 25 | $10.8M | $16.4M | ||
| Q2 25 | $-4.8M | $2.9M | ||
| Q1 25 | $1.9M | $4.0M | ||
| Q4 24 | $-7.2M | $53.0M | ||
| Q3 24 | $7.7M | $16.3M | ||
| Q2 24 | $11.1M | $14.0M | ||
| Q1 24 | $5.4M | $6.8M |
自由现金流率MEDRMAX
| Q4 25 | -8.8% | 47.1% | ||
| Q3 25 | 12.0% | 22.4% | ||
| Q2 25 | -4.5% | 4.0% | ||
| Q1 25 | 1.6% | 5.3% | ||
| Q4 24 | -6.1% | 73.2% | ||
| Q3 24 | 5.5% | 20.8% | ||
| Q2 24 | 6.6% | 17.8% | ||
| Q1 24 | 3.1% | 8.6% |
资本支出强度MEDRMAX
| Q4 25 | 1.8% | 10.4% | ||
| Q3 25 | 1.5% | 1.8% | ||
| Q2 25 | 1.3% | 2.2% | ||
| Q1 25 | 1.3% | 2.3% | ||
| Q4 24 | 1.9% | 9.1% | ||
| Q3 24 | 1.0% | 1.7% | ||
| Q2 24 | 1.1% | 2.4% | ||
| Q1 24 | 1.1% | 3.3% |
现金转化率MEDRMAX
| Q4 25 | — | 28.39× | ||
| Q3 25 | — | 4.45× | ||
| Q2 25 | -1.36× | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | 8.04× | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | 0.88× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MED
暂无分部数据
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
